Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, 12-Week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias

Next Previous
Trial Profile

A Phase 2, 12-Week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Preladenant (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme

Most Recent Events

  • 01 Mar 2011 Results published in the Lancet Neurology.
  • 17 Dec 2008 Status changed from active, no longer recruiting to completed, according to clinicaltrials.gov.
  • 24 Nov 2008 Results are expected to be presented at the 13th International Congress of the Parkinson's Disease and Movement Disorders in June 2009 according to a Schering-Plough media release; results were also reported in the media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top